<?php
include_once('.././common.php');
include_once(G5_PATH.'/head2.php');
?>

<div id="patients" class="main">
	<section class="visual el">
		<div class="inner">
			<div class="visual-txt">
				<h2>Regdanvimab</h2>
				<h3>IV injection 960mg/16mL</h3>
				<p>
					Regdanvimab is authorized for use under an EUA for the treatment of mild-to-moderate<br class="pc-b">
					coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg)<br class="pc-b">
					with positive results of direct SARS-CoV-2 viral testing.
				</p>
			</div>
			<!--visual-txt-->
			<ul class="about-ico">
				<li>
					<div class="icon"><img src="/img/icon1_02.png"></div>
					<p>
						Fact Sheet for Patients,<br>Parents and Caregivers<a href="#" target="_blank">English</a>
						<a href="#" target="_blank">Spanish</a>
					</p>
				</li>
				<li>
					<div class="icon"><img src="/img/icon1_01.png"></div>
					<p>Fact Sheet for Healthcare<br>Providers </p>
				</li>
				<li>
					<div class="icon"><img src="/img/icon1_03.png"></div>
					<p>FDA Letter of<br>Authorization</p>
				</li>
			</ul>
		</div>
	</section>
	<!--visual-->
	<section id="sec01" class="cont-a el">
		<div class="inner">
			<div class="cont-sec">
				<h2 class="cont-tit">Important facts about regdanvimab (CT-P59)</h3>
				<p>
					Regdanvimab is authorized for use under an EUA for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing.
				</p>
				<p>
					<ul class="cont-list">
						<li>Regdanvimab has not been approved, but has been authorized for emergency use by FDA</li>
					</ul>
				</p>
				<p class="p-bk">
					<i class="p-gr fas fa-external-link-alt"></i>
					For information on the authorized use of regdanvimab and mandatory requirements under the Emergency Use Authorization, please review the 
					<b class="p-gr ud-line">Fact Sheet for Patients, Parents and Caregivers (English)</b>, 
					<b class="p-gr ud-line">Fact Sheet for Patients, Parents and Caregivers (Spanish)</b>,
					<b class="p-gr ud-line">FDA Letter of Authorization.</b> 
				</p>
			</div>
			<!--cont-sec-->
			<div class="img-sec">
				<img src="/img/item_img.png">
			</div>
			<!--img-sec-->	
		</div>
	</section>
	<!--cont-a-->
	<section id="sec02" class="cont-c el">
		<div class="inner">
			<h2 class="cont-tit">What is COVID-19?</h3>
			<div class="explan">
				<p>
					COVID-19 is an infectious disease caused by a virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).<br>
					The virus spread when someone with the virus releases respiratory droplets and these droplets end up in the mouth, nose, or eyes of a person nearby.
				</p>
			</div>
			<!--explan-->
		</div>
	</section>
	<!--cont-b-->
	<section id="sec03" class="cont-d el">
		<div class="inner">
			<h2 class="cont-tit">What are the symptoms of COVID-19?</h3>
			<div class="explan">
				<p>
					Some signs and symptoms of COVID-19 include fever, cough, tiredness and shortness of breath.<br class="pc-b">
					The severity of these symptoms can range from mild to severe.<br class="pc-b">
					If not treated appropriately at early stages, it is likely that patients will develop severe symptoms.
				<p>
				<b class="p-gr">Speak to your healthcare provider by telephone, if you have concerns about your medication or symptoms.</b>
			</div>
			<!--explan-->
			<ul class="img-list">
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img01.png"></div>
					<p>Fever</p>
				</li>
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img02.png"></div>
					<p>Cough</p>
				</li>
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img03.png"></div>
					<p>Tiredness</p>
				</li>
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img04.png"></div>
					<p>Shortness of breath</p>
				</li>
			</ul>
			<!---->
			<h3 class="sub-tit3">Reference</h3>
			<ul class="cont-indt cont-list">
				<li>Mayo Clinic. Coronavirus disease 2019. Available at: <a href="http://www.mayoclinic.org/disease-conditions/coronavirus/symptoms-cause/syc-20479963" target="_blank">
				http://www.mayoclinic.org/disease-conditions/coronavirus/symptoms-cause/syc-20479963. Accessed Feb 2021.
				</a>
				</li>
				<li>Ge, J., Wang, R., Ju, B. et al. Nat  Commun 2021. DOI:10.1056/NEJMe2034495.</li>
			</ul>
		</div>
	</section>
	<!--cont-c-->
	<section id="sec04" class="cont-c el">
		<div class="inner">
			<h2 class="cont-tit">Why do I need monoclonal antibody (mAb) treatment?</h2>
			<div class="wr">
				<div class="explan">
					<p>
						Most COVID-19 patients are asymptomatic or recover from mild forms of the disease, but high-risk patients  (older adults [>60 years], with underlying diseases [CVD, lung]) are more likely to reach severe phases leading to hospitalization, oxygen therapy and high possibility of mortality.
					</p>
					<p>
						Monoclonal antibody treatment initiated at an early phase can reduce the progression rate to severe COVID-19 in mild-to-moderate patients.
					</p>
				</div>
				<div class="img-sec"><img src="/img/pt/sptm_img05.png"></div>
			</div>
			<div class="cont-sec">
				<h3 class="sub-tit3" style="margin-left:0;">Reference</h3>
				<ul class="cont-list">
					<li>Hosseini EH., Kashani RN., Nikzad H, et al. Virology. 2020 Dec; 551:1-9. DOI: 10.1016/j.virol.2020.08.011.</li>
					<li>Cohen MS. N Engl J Med 2021; 382:289-291. DOI: 10.1056/NEJMe2034495</li>
					<li><a href="https://www.who.int/westernpacific/emergencies/covid-19/information/high-risk-groups" target="_blank">https://www.who.int/westernpacific/emergencies/covid-19/information/high-risk-groups</a></li>
				</ul>
			</div>
		</div>
	</section>
	<section id="sec05" class="cont-f el">
		<div class="inner">
			<h2 class="cont-tit">What is regdanvimab?</h2>
			<div class="wr">
				<div class="explan">
					<p>
						Regdanvimab was identified as a potential treatment for COVID-19 through screening of antibody candidates, of which it showed the highest potency in neutralizing the SARS-CoV-2 virus. Regdanvimab blocks SARS-CoV-2 from binding to the angiotensin-converting enzyme 2 (ACE2) receptor and therefore prevents the virus from entering into human cells.
					</p>
					<p>
						In addition, in vitro and in vivo studies show that regdanvimab strongly binds to the receptor binding domain (RBD) of SARS-CoV-2â€™s spike protein(s) and significantly neutralises the wild type and mutant viruses of concern, including the Alpha variant (B.1.17), Beta (B.1.351), Gamma (P.1), Delta (B.1.167.2) and the previously identified seven clades of SARS-CoV-2 (S/L/V/G/GH/GR/GV).
					</p>
				</div>
				<div class="video-sec">
					<p>Mechanism of Action Video</p>
					
					<iframe width="560" height="315" src="https://www.youtube.com/embed/HLOUUbupcFQ" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
				</div>
			</div>
			<div class="">
				<h3 class="sub-tit3" style="margin-left:0;">Reference</h3>
				<ul class="cont-list">
					<li>Ryu DK, et al. Biochem Biophys Res Commun. 2021;556:135-140.</li>
					<li>Ryu DK, et al. bioRxiv., Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2, Posted July 09, 2021. [Preprint]</li>
					<li>Ryu DK, et al. bioRxiv., The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2, Posted July 23, 2021. [Preprint]</li>
				</ul>
			</div>
		</div>
	</section>
	<section id="sec06" class="cont-e el">
		<div class="inner">
			<h2 class="cont-tit">Who is regdanvimab for?</h2>
			<div class="explan">
				<p>
					Regdanvimab should be administered as soon as possible after a positive viral test for SARS-CoV-2 and within 10 days of symptom onset in adults and<br class="pc-b"> pediatric patients (12 years of age and older weighing at least 40 kg).
				</p>
			</div>
		</div>
	</section>
</div> 
<?php
include_once(G5_PATH.'/tail.php');
?>